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Background. Annexin A2 is a peripheral membrane protein that belongs to the annexin family of Ca
2+ and phospholipid-
binding proteins. This protein, which plays a role in membrane organization and dynamics in particular along the endocytic
pathway, exists as a heterotetrameric complex, consisting of two annexin A2 molecules bound via their N-termini to a dimer of
p11/S100A10 light chains. The light chain, and thus presumably formation of the heterotetramer, was reported to control
annexin A2 association to the plasma membrane and to cortical actin, as well as the distribution of recycling endosomes.
However, the specific role of the light chain and the functions of monomeric versus heterotetrameric annexin A2 have
remained elusive in the endocytic pathway. Methodology/Principal Findings. Here, we have investigated whether p11 plays
a role in the endosomal functions of annexin A2. Using morphological and biochemical approaches, we found that p11, unlike
annexin A2, was not present on early endosomes. Neither was the heterotetramer detected on purified early endosomes, while
it was clearly present in total cell lysates. Moreover, knockdown of p11 with siRNAs did not affect annexin A2 targeting to early
endosomes, and, conversely, binding of annexin A2 to purified endosomes or liposomes occurred without p11 in vitro. Finally,
while we could confirm that annexin A2 knockdown inhibits transport beyond early endosomes, p11 knockdown had no such
effects on early-to-late endosome transport. Conclusions/Significance. Our data show that the binding of annexin A2 to
endosomal membranes and its role in endosomal trafficking are independent of the p11/S100A10 light chain. We thus
conclude that annexin A2 functions are fully supported by the monomeric form of the protein, at least the endocytic pathway
leading to lysosomes.
Citation: Morel E, Gruenberg J (2007) The p11/S100A10 Light Chain of Annexin A2 Is Dispensable for Annexin A2 Association to Endosomes and
Functions in Endosomal Transport. PLoS ONE 2(10): e1118. doi:10.1371/journal.pone.0001118
INTRODUCTION
Annexins form a family of peripheral membrane proteins that can
coordinate Ca
2+ ions via conserved a-helical repeats (annexin
repeats). Most members of this family also share the capacity to
bind negatively charged phospholipids and thus membranes, and
are believed to play a role in membrane organization and
dynamics, perhaps as scaffold proteins [1,2,3]. Like the majority of
annexins, annexin A2 (AnxA2) is composed of a conserved C-
terminus core domain folded via annexin repeats and a hypervari-
able non-folded N-terminus. AnxA2 N-terminal domain is small
(24 amino acids) and bears two putative phosphorylation sites
Tyr23 and Ser25, which are presumably targets of Src kinase and
protein kinase C, respectively [4,5,6], as well as the binding site for
its natural ligand p11/S100A10 [2,7,8]. Interactions of two
molecules of AnxA2 with two molecules of p11 lead to the
formation of the (AnxA2)2-(p11)2 heterotetramer [9]. It has been
reported that the p11 light chain is required for AnxA2 binding to
the plasma membrane and to the cortical actin network [10], both
mechanisms being also regulated by the presence of Ca
2+ [2,3].
Evidence also suggests that the (AnxA2)2-(p11)2 heterotetramer
plays a role in the subcellular distribution of early and recycling
endosomes [11,12] and in the channel functions of cystic fibrosis
conductance regulator protein CFTR [13].
AnxA2 has been shown to play a crucial role at early stages of
the endocytic pathway by participating to both the recycling
pathway [12] and the degradation pathway leading to late
endosomes and lysosomes [14,15]. The protein is present on early
endosomes [16], but, unlike other members of this protein family,
membrane association does not depend on calcium ions [16,17],
but on membrane cholesterol [14,15,18], suggesting that AnxA2
binds to or participates in the formation of cholesterol-rich
platforms on endosomal membranes. Moreover, this Ca
2+-in-
dependent endosomal localization depends on the small hyper-
variable N-terminal domain of AnxA2 [15,17,18,19] which also
contains not only phosphorylation sites but the p11 binding region.
In the present study, we have investigated the putative role of
the p11 light chain in AnxA2 association to early endosomes and
in endosomal trafficking. We report that, in contrast to AnxA2,
p11 is not present on early endosomes, and that the (anxA2)2-
(p11)2 heterotetramer is not detected on purified endosomes.
Moreover, we find that silencing p11 expression does not affect
AnxA2 targeting to early endosomes in vivo. Consistently, AnxA2
binding to liposomes or purified endosomes occurs without p11 in
vitro. Finally we show that downregulation of p11 has no effect on
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PLoS ONE | www.plosone.org 1 October 2007 | Issue 10 | e1118transport from early to late endosome — in marked contrast to
AnxA2 downregulation [15]. We conclude that AnxA2 functions
are fully supported by the monomeric form of the protein in the
endocytic pathway leading to lysosomes.
RESULTS
Morphological analysis of p11 subcellular
distribution
To investigate the putative p11-AnxA2 interplay, we first
compared p11 subcellular localization in HeLa cells to that of
anxA2 by light microscopy. To this end, we used a special triton-
based permeabilization buffer that allowed better p11 detection
and analysis by immunofluorescence (Fig 1C, see methods), when
compared to the more conventional saponin-based protocol
(Fig 1A). Then, p11 showed a reticulo-vesicular pattern (Fig 1C,
left and right panels) and often appeared concentrated, like AnxA2
(Fig 1B), at sites where F-actin patches were observed at, or close
to, the cell surface (arrowheads in Fig 1C). Consistently, p11 and
AnxA2 showed extensive colocalization at the plasma membrane
and in structures reminiscent of actin-positive structures (Fig 1D,
see arrows). However, in marked contrast to AnxA2 [15,16] (see
Fig 5D), p11 was not detected on early endosome labeled with
antibodies against EEA1 (Fig 2A), an effector of the small GTPase
Rab5. As expected, p11 also failed to colocalize with the late
endocytic marker Lamp1, a trans-membrane glycoprotein (Fig 2B).
We thus concluded that p11 could not be detected on early or late
endosomes.
Biochemical analysis of p11 distribution
We analyzed p11 distribution biochemically, using a well-
established protocol for the fractionation of endosomes from
BHK cells (see methods [20]). While p11 was abundant in the total
cell lysate, the protein could not be detected in purified early
endosomal fractions containing AnxA2 and Rab5 (Fig 3A, left
panel). Quantification of the western blot signals from three
independent experiments showed that the p11 over AnxA2 ratio
dropped in early endosomes to approximately 1/10
th of the value
measured in total lysates (Fig 3A, right panel). By contrast, the p11
over AnxA2 ratio increased approximately 5 fold in cytosol when
compared to total membranes, after high speed centrifugation.
AnxA2 and Rab5 co-fractionated predominantly with mem-
branes, as expected (Fig 3B). These observations led us to conclude
that p11 does not cofractionate with early endosomal membranes.
We then investigated whether the AnxA2-p11 complex could be
retrieved from endosomes by immunoprecipitation. For this
purpose, we used human AnxA2, but with the alanine residue at
position 65 replaced with an aspartic acid, which is found at the
corresponding position in the porcine sequence [21]. The A65E
mutant is only detected by the H28 anti-AnxA2 antibody, and will
be referred to in the paper as AnxA2
H28. Additionally, the HH7
monoclonal antibody recognizes selectively endogenous AnxA2 in
Figure 1. subcellular localization of p11 compared to F-actin and annexin A2. The distribution in HeLa cells of p11 (H21 monoclonal antibody),
AnxA2 (HH7 monoclonal antibody, and F-actin (phalloidin) was analyzed by immunofluorescence using a conventional saponin-based
permeabilization protocol (A) or a protocol optimal for AnxA2 and p11 detection after cytosol wash-out (B–D), as follows: (A) p11 and F-actin
double fluorescence after saponin-based permeabilization; (B) AnxA2 and F-actin double fluorescence after cytosol wash-out; (C) p11 and F-actin
double fluorescence analysis after cytosol wash-out; (D) p11 and AnxA2-GFP double fluorescence analysis after cytosol wash-out. Arrowheads in B
and C indicate concentrated AnxA2 and/or p11 bundles at cell surface, with strong colocalization with F-actin. Arrows in D indicate p11/AnxA2
colocalization. Bar: 10 mm.
doi:10.1371/journal.pone.0001118.g001
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against EEA1 (A) and Lamp1 (B). Since AnxA2 is present on early endosomes, we used wide field, and not confocal, microscopy in (A) to ensure that
structures that may contain both p11 and the early endosomal marker EEA1 were not missed in this analysis (hence some background nuclear
staining). Cropped images are shown on both right panels. Bar: 10 mm.
doi:10.1371/journal.pone.0001118.g002
Figure 3. biochemical analysis of p11 distribution and annexin A2/p11 interaction detection. (A), Total cell lysates and early endosomes (EE) were
prepared from BHK cells, and then analyzed by SDS gels (equal proteins amounts loaded in each lane) and western blotting using the indicated
antibodies. The p11 and AnxA2 signals were scanned and the right panel shows the ratio of the p11 over AnxA2 signals in the corresponding
fractions (A.U: arbitrary units). (B) Experiments and quantification (right panel) were as in (A) except that total membranes and cytosol obtained after
high speed centrifugation were analyzed. (C) Hela cells were transfected with (AnxA2
H28-GFP), and cell lysates were prepared. Then, AnxA2-GFP was
immunoprecipitated from the lysates with anti-GFP antibodies (IP: immunoprecipitate; Ab- : control without the specific antibody; load: input fraction
before immunoprecipitation). Samples were then analyzed by SDS gels and western blotting with the indicated antibodies. The H28 antibody only
recognizes AnxA2
H28, while, in our hands, the HH7 antibody recognizes WT endogenous AnxA2. HC IgG, heavy chain of anti-GFP antibody used for
immunoprecipitation. (D) The experiments were as in (C), except that purified early endosomes were used as starting materials. The left panel shows
western blots with anti-GFP antibody, while the right panels show blots with anti-AnxA2 antibody. For comparison, the small right panel (EE load)
indicates the mobility of (untagged) AnxA2 in a gel of the early endosome (EE) starting material (load). HC IgG, heavy chain of anti-GFP antibody used
for immunoprecipitation, LC IgG, light chain of anti-GFP antibody.
doi:10.1371/journal.pone.0001118.g003
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hands, to detect recombinant or GFP-tagged anxA2
H28. When
expressed in HeLa cells, GFP-AnxA2
H28 was properly targeted to
early endosomes (Fig 3D, 5D). Then, p11 was efficiently co-
immunoprecipitated together with AnxA2
H28-GFP from total cell
lysates, using anti-GFP antibody (Fig 3C), further demonstrating
that the A65E mutation did not affect the AnxA2 p11 binding site.
Similarly, endogenous AnxA2 was also co-immunoprecipitated
with AnxA2
H28-GFP (Fig 3C), demonstrating that endogenous
AnxA2 copurified with both AnxA2
H28-GFP and p11 within the
same complex, presumably as a (AnxA2
H28-GFP)-(AnxA2)-(p11)2
heterotetramer. These immunoprecipitation experiments were
then carried out using early endosomes purified from BHK cells
expressing AnxA2
H28-GFP. While AnxA2
H28-GFP was efficiently
immunoprecipiated from purified endosomes, p11 could not be
detected in the early endosomal fractions used as starting materials
as expected (Fig 3A), let alone in the immunoprecipitates (Fig 3D).
Neither was endogenous AnxA2 (Fig 3D), suggesting that
endosomal AnxA2
H28-GFP was monomeric and not complexed
to other AnxA2 molecules as a heterotetramer. Altogether these
observations indicate that p11 cannot be detected on endosomes
biochemically or morphologically.
Interactions of monomeric annexin A2 with
endosomes and liposomes
Since our immunoprecipitations experiments suggested that
monomeric AnxA2 was present on endosomes, we tested whether
the monomer indeed had the capacity to bind endosomal
membranes in vitro. Early endosomal fractions prepared from
BHK cells were incubated for 30 minutes at 37uC with purified
recombinant human AnxA2
H28 in the absence of cytosol, and then
endosome-associated AnxA2 was separated from free AnxA2 by
sedimentation (see methods). Recombinant (AnxA2
H28) and
endogenous AnxA2 could then be detected selectively using the
H28 and HH7 antibodies, respectively (Fig 4A–B and [10,23]).
This analysis demonstrated that monomeric AnxA2 could bind
early endosomal membranes with high efficiency (Fig 4A left
panel). Since purified early endosomes contain endogenous
AnxA2, one may envision that the exogenously added recombi-
nant AnxA2
H28 interacted with endogenous AnxA2 present on
endosomes. However, monomeric AnxA2
H28 also associated with
high efficiency to PA:PE:cholesterol liposomes (Fig 4A, right
panel), which can fully support AnxA2 binding in vitro [15]. These
experiments thus demonstrate that monomeric AnxA2 exhibits the
intrinsic capacity to bind endosome and liposome membranes in
the absence of the light chain p11.
Endosomal targeting of annexin A2 is not modified
after p11 knockdown
Since monomeric AnxA2 efficiently bound membranes in the
absence of p11 in vitro, we then investigated whether AnxA2 was
properly targeted to endosomes in vivo, when p11 expression was
silenced. Knockdown of p11 in HeLa cells could be achieved with
either one of two siRNAs, siRNA2 being more efficient (Fig 5A).
Downexpression of p11 with siRNA2 had no effect on the total
cellular amounts of AnxA2 or Rab5 (Fig 5B). Conversely, efficient
downexpression of AnxA2 using Dicer-generated siRNAs did not
affect p11 expression (Fig 5B). It is, however, possible that p11
silencing interfered with the capacity of AnxA2 to interact with
membranes, without affecting its level of expression. We thus
prepared post-nuclear supernatants (PNS) from mock-treated or
p11 siRNA2-treated HeLa cells (Fig 5C left panel), which were
then further fractionated by floatation in gradients to purify
membrane fractions containing both early and late endosomes
(Fig 5C right panel), [24]. No difference in the amount of
membrane-associated AnxA2 was observed when comparing total
endosomal fractions from mock-treated or p11 siRNA2-treated
HeLa cells (Fig 5C right panel). When mock-treated cells were
analyzed by immunofluorescence, AnxA2 showed a characteristic
endosome-like punctate pattern and colocalized extensively with
EEA1, consistently with its distribution to early endosomes [15,16]
(Fig 5D, left panel, arrowheads). After p11 knockdown (Fig 5D,
right panel, arrowheads), we did not observe any difference in
AnxA2 distribution and in the colocalization of AnxA2 with EEA1
(quantification shows that the number of EEA1-positive vesicles
that contained AnxA2 after p11 knockdown was essentially
identical to the mock-treated control, corresponding to
104%61.4). Altogether these data show that p11 silencing has
no effect on anxA2-targeting to early endosomes.
Early to late endosomal transport is not affected by
the absence of p11
In previous studies, we found that AnxA2 knockdown selectively
inhibits the transport of endocytosed tracers from early to late
endosomes: newly-formed multivesicular endosomes do not detach
Figure 4. recombinant annexin A2 binding to endosome and
liposome membranes. (A) Early endosomes (left panel) or PA/PE/
cholesterol liposomes (right panel) were prepared and incubated in
vitro for 30min at 37uC with 5 mg purified recombinant AnxA2
(AnxA2
H28). Membrane-bound and free AnxA2 were then separately
recovered after high speed centrifugation, and analyzed by SDS gels
and western blotting, as indicated. The faster migrating form of AnxA2
in panel A corresponds to the core domain of the protein lacking the N-
terminus, and results from AnxA2 proteolytic cleavage. Note that the
core domain does not become efficiently membrane-associated, as
expected [15], (B) The recombinant mutant AnxA2
H28 is selectively
detected with the monoclonal antibody H28 (see 4A), which does not
detect WT AnxA2 [23], while the HH7 monoclonal antibody recognizes
WT AnxA2 [10], as shown with blots of HeLa and BHK lysates.
doi:10.1371/journal.pone.0001118.g004
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late endosomes [15]. We thus investigated whether p11 was
required to support these functions of AnxA2 in endosomal
transport. When mock-treated HeLa cells were incubated with
rhodamin-dextran for 10min at 37uC, the tracer reached early
endosomes containing AnxA2, EEA1 and Rab5 (not shown)
[15,25,26]. After a subsequent 40min incubation in marker-free
medium, the tracer reached late endosomes containing Lamp1
(Fig 6A–B, left panels), as expected [15,25,26]. Knockdown of
AnxA2 had no effect on rhodamin-dextran transport to early
endosomes (not shown), consistently with our previous observa-
tions [15]. After the chase, however, rhodamine-dextran failed to
reach Lamp1-positive late endosomes and was no longer detected
intracellularly in cells lacking AnxA2 (Fig 6B, right panels; the
number of vesicles containing Lamp1 and dextran was reduced to
7.2%61 of the mock-treated control after AnxA2 knockdown).
Most likely, the tracer had then been recycled to the medium,
rather than transported to late endosomes and lysosomes [15].
Figure 5. endosomal targeting of annexin A2 is not affected when p11 is downregulated. (A) p11 was downregulated in HeLa cells using two
siRNA duplexes (RNAi1 and RNAi2), and lysates were prepared. The control (ctrl RNAi) siRNA used was designed against viral stomatitis virus (VSV-G)
G-protein, which is not expressed in HeLa cells; equal amount of proteins were loaded in each lane and tubulin was used as an equal loading marker.
(B) AnxA2 (diced AnxA2 RNAi) or p11 (RNAi2) was downregulated in HeLa cells, and total lysates were analyzed by western blotting as indicated (C)
p11 was knocked down (as in A–B), and then a post-nuclear supernatant was prepared (left panel) and used as to further fractionate total endosomes
(right panel). The samples were then analyzed by western blotting using the indicated antibodies. (D) AnxA2-GFP (AnxA2
H28-GFP) was expressed in
mock-treated (left panel) or p11-siRNA2-treated HeLa cells (right panel) and then cells were processed for immunofluorescence as in Fig 1 (using the
special permeabilizaiton protocol). Arrows show AnxA2-GFP/EEA1 colocalizations and cropped images are shown under both conditions. Bar: 10 mm.
doi:10.1371/journal.pone.0001118.g005
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knockdown, while internalization and recycling did not appear to
be significantly affected, as shown previously [15]. Downexpres-
sion of p11 did not affect the internalization of rhodamin-dextran
into early endosomes (not shown), much like in mock-treated cells
or cells lacking AnxA2. However, in marked contrast to the fate of
the tracer in AnxA2-silenced cells, rhodamin-dextran was
transported after the chase to Lamp1-positive late endosomes in
p11 knockdown cells as efficiently as in mock-treated cells (Fig 6A,
right panels, the number of vesicles containing Lamp1 and
dextran after p11 knockdown was essentially identical to the mock-
treated control corresponding, corresponding to <94%61). We
thus conclude that AnxA2 functions in membrane transport from
early to late endosomes are independent of the light chain p11.
DISCUSSION
Members of the annexins family are believed to be involved in
a wide range of biological functions and the specificity of these
functions can presumably be determined by proper targeting to
the correct membrane or membrane domain. The AnxA2/p11
heterotetramer is believed to play a role in exocytosis [27], and at
the plasma membrane in membrane scaffolding during macro-
pinocytosis [28] and junctional platforms formation [29]. More-
over, in addition to its functions in the degradation pathway
leading to late endosomes and lysosomes [15] (and this study),
AnxA2 also plays a role in the recycling pathway, perhaps as
a heterotetramer [12]. In addition, it has also been suggested that
annexin A1, which is closely related to AnxA2, is targeted to early
endosomes with its light chain p10/S100C/S100A11, most
probably as a tetrameric complex [30].
Here, we demonstrate that AnxA2 functions in endosomal
membrane transport do not depend on the light chain p11.
Previous studies from others [17,19] and us [15,18] have shown
that AnxA2 association to early endosomes does not depend on
calcium ions but on membrane cholesterol, and requires the small
N-terminal domain of the protein, which contains the p11 binding
site and the phosphorylation sites. This is further illustrated by the
fact that the core domain alone (lacking the N-terminus) does not
bind bilayers in the absence of calcium [15]. One might thus
envision that the N-terminal region of AnxA2 cannot accommo-
date p11 spatially while fulfilling the endosomal functions of the
protein. The short AnxA2 N-terminus may form an amphipathic
helix [31,32], and structural studies revealed that p11 binds an N-
terminal AnxA2 peptide through hydrophobic interactions [9]. It
is thus conceivable that, in the absence of p11, the N-terminal
amphipathic helix dips into the bilayer [33] and interacts with lipid
tails and perhaps cholesterol itself.
Future work will clearly be necessary to determine why the p11
light chain seems dispensable for AnxA2 functions in the
degradation pathway (this study), while the (AnxA2)2-(p11)2
heterotetramer plays a role in the subcellular distribution of early
and recycling endosomes [11,12]. One might, however, speculate
that calcium-dependent membrane association, e.g. at the plasma
membrane or along the protein recycling pathway, are regulated
by p11 binding and heterotetramer formation [8]. Indeed, the p11
light chain appears to be necessary for AnxA2 binding to the
plasma membrane and to the cortical actin network [10], both
mechanisms being also regulated by the presence of Ca
2+ [2,3]. In
addition, (AnxA2)2-(p11)2 association to the plasma membrane
seems to be regulated by direct binding of the heterotetramer to
phosphatidylinositol (4,5) bisphosphate [34,35] and p11 itself
seems to play a role in the trafficking of some ion channels and
receptors — reviewed in [8]. Rescher and Gerke thus recently
proposed that p11 tethers some transmembrane proteins to
Figure 6. p11 downregulation does not alter transport from early to late endosomes. Rhodamin-dextran was endocytosed for 10 min at 37uC and
then chased for 40 min in marker-free medium, after p11 knockdown as in Fig 5 (left panels, with the corresponding mock-treatment on the left) or
AnxA2 knockdown as in Fig 5 (right panels, with the corresponding mock-treatment on the left). Cells were then processed for immunofluorescence
using the indicated antibodies as in Fig 1. Bar: 10 mm.
doi:10.1371/journal.pone.0001118.g006
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helps their transport to the plasma membrane [8]. It is conceivable
that specific functions of AnxA2 are differentially regulated at
different sites and along different trafficking routes by separate
mechanisms.
MATERIALS AND METHODS
Cells, antibodies and reagents
Baby Hamster kidney cells (BHK21) and HeLa cells were grown
as previously described [15]. The monoclonal antibody against
Rab5 was a gift from R. Jahn (Go ¨ttingen, Germany), monoclonal
antibodies against AnxA2 (HH7 and H28) and p11/S100A10
(H21), were gifts from V. Gerke (Mu ¨nster, Germany,
[10,21,22,23]). Rabbit polyclonal antibodies against EEA1 (early
endosomal antigen 1) and Lamp1 (lysosomal associated membrane
protein 1) were from Alexis Biochemical and Affinity Bioreagents
respectively. Monoclonal antibody against tubulin was from
Sigma. Monoclonal antibody against GFP was from Roche
Diagnostics. Peroxidase-conjugated secondary antibodies were
from BioRad and Cy2, Cy3 and Cy5-conjugated fluorescent
secondary antibodies were from Jackson Immunoresearch. 10,000
Da rhodamin-dextran as fluorescent fluid phase marker was from
Molecular Probes. F-actin was labeled with Allexa fluor 486nm
coupled phalloidin (Invitrogen).
Plasmids, recombinant proteins and RNAi
cDNA plasmid coding for human AnxA2A65E -GFP, which is
here referred to as AnxA2
H28 because of the presence of the H28
antibody epitope, was a gift from V. Gerke (Mu ¨nster, Germany).
For recombinant AnxA2 construction, human AnxA2
H28 cDNA
was cloned in pGEX-5X-1 expressing vector (Clontech) and GST-
protein was produced in BL21 bacteria strain. The GST tag was
removed by Factor Xa cleavage and benzamidine treatment
(Amersham). The quality of recombinant protein was checked by
SDS-PAGE and Coomassie staining. For p11 downregulation, two
21 nucleotides RNA duplexes (DNA target sequence 1: AAC
GGA CCA CAC CAA AAT GCC and DNA target sequence 2:
AAT GCC ATC TCA AAT GGA ACA) of the human p11
sequence were obtained from Qiagen-Xeragon; for ctrl siRNA, we
used VSV-G (Vesicular Stomatisis Virus, protein G) siRNA.
AnxA2 downregulation was obtained by Dicer-generated siRNA
duplexes. Briefly, an amplicon of the target sequence (nucleotides
1–320 from human AnxA2 cDNA, PCR oligos for T7-promoter
based cloning: TAA TAC GAC TCA CTA TAA GGG AGA
ATG TCT ACT GTT CAC G sense and TAA TAC GAC TCA
CTA TAG GGA GAC TGA GCA GGT GTC TTC antisense)
was transcribed in vitro to generate dsRNA; dicing reaction and d-
siRNAs purification were done accordingly to the manufacturer’s
instructions (Invitrogen). HeLa and BHK cells were transfected
with Fugene-6 (Roche Diagnostics) 6 h after seeding for cDNA
transfection (total time of overexpression: 48 h) and with
lipofectamine 2000 (Invitrogen) 24 h after seeding for RNAi
experiments (total time for silencing: 72 h).
Microscopy
Cells cultured on coverslips were fixed with 3% PFA and
permeabilized with 0.1% saponin in PBS/serum buffer except
when using special permeabilization buffer, before fixation,
containing 0.1% Triton 1006 in 100 mM KCl, 2 mM MgCl2,
1 mM CaCl2 and 1 mM Hepes pH 6.9. Pictures were captured
with a Zeiss Axiophot microscope equipped with a 636 Plan-
Neofluar objective or with a Zeiss LSM 510 META confocal
microscope equipped with a 636Plan-Apochromat objective and
HeNe1, HeNe2 and Argon lasers. To quantify the colocalization
between EEA1 and AnxA2-GFP in mock- and p11 RNAi-treated
cells, we counted the number of EEA1-positive structures that also
contained AnxA2-GFP per 100 mm
2 in each focal plane. Similarly,
the number of vesicles containing Lamp1 and rhodamin-dextran
(after pulse-chase internalization as above) after mock-, p11, or
AnxA2-RNAi was quantified by counting the number of vesicles
containing both markers per 100 mm
2 in each focal plane.
In vivo endocytic transport assay
Cells were grown on coverslips and then incubated with 3 mg/mL
rhodamin-dextran for 10 min at 37uC in GMEM containing
10 mM Hepes medium. Alternatively, cells were re-incubated in
marker-free medium for an additional 40 min at 37uC. Then, cells
were fixed and processed for immunofluorescence, as above.
Subcellular fractionation
Early and late endosomes were purified as previously described
[20] from BHK cells. A total endosomal fraction was prepared
from HeLa cells, as described [24]. The analysis of total
membranes and cytosol was carried out by high-speed centrifu-
gation of post-nuclear supernatants at 70.000 rpm for 30 min.
Membranes and cytosol were recovered from the high-speed pellet
(HSP) and high-speed supernatant (HSS), respectively.
Annexin A2 binding to liposomes and endosomes
5 mg of purified recombinant AnxA2 (AnxA2
H28) were incubated
for 30 min at 37uC with liposomes containing phosphatidic acid
(PA):phosphatidylethanolamine (PE):cholesterol, (2:2:1) or with
purified early endosomes in 50 mM Hepes, 1mM EGTA (pH 7.4),
100 mM KCl buffer. Binding was analyzed after separation of
membrane-bound and free AnxA2 by ultracentrifugation at
35.000 rpm for 60 min at 4uC. Lipids used for liposomes
preparation (PA, PE and cholesterol) were from Sigma.
Biochemical analysis
Total cell lysates were prepared using TNE buffer (20 mM tris
pH 7.4, 150 mM NaCl, 1 mM EDTA), and proteases inhibitors
(aprotinin, leupeptin and pepstatin) and 1% NP40. For immuno-
precipitation assays, this lysis buffer was supplemented with 10%
glycerol. Briefly, cell extracts from transfected BHK or HeLa cells
were diluted with TNE buffer to a final NP40 concentration of 1%,
complemented with 4 mg anti-GFP antibody and proteinA-Sephar-
ose beads (Amersham), and incubated for 2 h at 4uC. Beads were
then washed with TNE buffer with 10%glycerol and resuspended in
Laemmlibuffer[36].Lysatesandimmunoprecipitateswereanalyzed
bySDS-PAGE,using12%acrylamidegels,andwesternblotting.For
p11 western blotting analysis, PVDF (Millipore) membranes were
used. Western blotting was carried out using the SuperSignalH West
Pico chemiluminescent substrate (Pierce Chemical Co); exposure
times were always within the linear range of detection. Chemilumi-
nescent signal was quantified with ImageJ software (NIH).
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